REG - ValiRx PLC - Director/PDMR Shareholding

ValiRxAnnouncement

Today 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260304:nRSD2124Va&default-theme=true

RNS Number : 2124V  ValiRx PLC  04 March 2026

ValiRx PLC

("ValiRx" or the "Company")

Director/PDMR Shareholding

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health, announces that it received
notification on 3 March 2026 that Mark Eccleston, Chief Executive Officer,
made the following purchase of ordinary shares in the Company.

 

 Director        Purchase price (Aggregated)  Ordinary shares purchased  Resultant interest in ordinary shares  Resultant percentage of issued ordinary shares
 Mark Eccleston  0.33 pence                   1,000,000                  59,746,187                             8.04%

 

Further details are set out in the Notification of Dealing Form below.

 

This announcement contains inside information for the purposes of the UK
Market Abuse Regulation and the Directors of the Company are responsible for
the release of this announcement.

 

*** ENDS ***

 

Engage with the ValiRx management team directly by asking questions, watching
video
summaries and seeing what other shareholders have to say. Navigate to
our Interactive Investor
hub here: https://valirx.com/s/cc8ef3
(https://valirx.com/s/cc8ef3)

 

For more information, please contact:

 

 Investor questions on this announcement           https://valirx.com/link/peg6vy (https://valirx.com/link/PBvBVP)

 We encourage all investors to share questions

 on this announcement via our investor hub
 ValiRx plc                                        Tel: +44 115 784 0026

                                                   www.valirx.com (http://www.valirx.com)

 Dr Mark Eccleston, CEO                            Mark.Eccleston@valirx.com

 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray / Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath
 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                               lucy@vformation.biz

                                                   sue@vformation.biz

 

Subscribe to our news alert service: https://valirx.com/s/f298d1
(https://valirx.com/s/f298d1)

 

Notes for Editors

 

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

 

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

 

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

 

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

 

For further information, visit: www.valirx.com (http://www.valirx.com)

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 1   Details of the persons discharging managerial responsibilities / person
     closely associated

 a)  Name                                    Mark Eccleston

 2   Reason for the notification

 a)  Position/Status                         Chief Executive Officer

 b)  Initial notification/ Amendment         Initial

 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor

 a)  Name                                    ValiRx PLC

 b)  LEI                                     213800VQKB9SJCQDET40

 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted

 a)  Description of the financial

     instrument, type of

     instrument                              Ordinary shares

     Identification code

                                             GB00BLH13C52

 b)  Nature of the transaction               Purchase of shares

 c)  Price(s) and volume(s)

Price(s)    Volume(s)
                                             0.33 pence  1,000,000

 
 d)  Aggregated information

     -      Aggregated volume                N/A

     -      Price

 e)  Date of transaction                     3 March 2026

 f)  Place of transaction                    AIM

 

d)

Aggregated information

 

-      Aggregated volume

 

-      Price

 

 

 

N/A

 

e)

Date of transaction

 

3 March 2026

f)

Place of transaction

 

AIM

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHDBGDXRSGDGLX



            Copyright 2019 Regulatory News Service, all rights reserved